Cough-variant asthma
Conditions
Interventions
Treatment group:Inhaled glucocorticoids combined with long-acting ß2 receptor agonists (ICS+LABA) were administered for 8 weeks, specifically budesonide formoterol 160 µ g/4.5 µ g, 1 inhalation each t
Control group:Inhaled glucocorticoids combined with long-acting ß2 receptor agonists (ICS+LABA) were administered for 8 weeks, specifically budesonide formoterol 160 µ g/4.5 µ g, 1 inhalation each tim
Sponsors
Tongji Hospital of Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 70; 2. According to the "Guidelines for the Diagnosis and Treatment of Cough (2021)" issued by the Asthma Group of the Chinese Thoracic Society of the Chinese Medical Association, the diagnostic criteria for cough variant asthma (CVA) are met: cough is the main or sole symptom, often accompanied by obvious nocturnal irritating cough, and the course of the disease is more than 8 weeks. Positive bronchial provocation test, or the average diurnal variation rate of peak expiratory flow rate during the day is greater than 10%, or positive bronchial dilation test; The anti-asthma treatment is effective. 3. Visual Analogue Scale (VAS) for cough >=40mm; 4. Sign the informed consent form and indicate the date.
Exclusion criteria
Exclusion criteria: 1. Those who are currently smoking or have quit smoking for less than two years; 2. Those who have a history of respiratory tract infection in the 8 weeks prior to the assessment; 3. Those with liver or kidney diseases that affect drug metabolism; 4. Those who need to use angiotensin-converting enzyme inhibitors (ACEI) for a long time; 5. Those who have started the treatment of cough with macrolide antibiotics or proton pump inhibitors within 12 weeks before the first administration; 6. Those with hypertension or other cardiovascular system diseases; 7. Those who have contraindications or allergies to the investigational drugs; 8. Those with concurrent mental disorders or drug dependence; 9. Pregnant or lactating women; 10. The researcher determines that there are any other circumstances that make one unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour cough frequency; | — |
Secondary
| Measure | Time frame |
|---|---|
| daytime and nocturnal cough symptom scores;Cough visual analogue scale (VAS) score;Hull Airway Reflux Questionnaire (HARQ) score;capsaicin cough sensitivity;Leicester Cough Questionnaire (LCQ);Newcastle Laryngeal Hypersensitivity Questionnaire;Depression Screening Scale (PHQ-9);Depression Screening Scale (PHQ-9);Security Index; | — |
Countries
China
Contacts
Public ContactXu Xianghuai
Tongji Hospital of Tongji University
Outcome results
None listed